Identificationof novel therapeutic options for venetoclax-resistant AML cells through drug repurposing.

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F23%3A00130270" target="_blank" >RIV/00216224:14740/23:00130270 - isvavai.cz</a>
Result on the web
<a href="https://www.phd.cz/pdf/PHD-2023_HEMATOLOGIE-2023_Program-sekce-NLZP.pdf" target="_blank" >https://www.phd.cz/pdf/PHD-2023_HEMATOLOGIE-2023_Program-sekce-NLZP.pdf</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Identificationof novel therapeutic options for venetoclax-resistant AML cells through drug repurposing.
Original language description
Acute myeloid leukemia (AML) is a malignant disease derived from the bone marrow precursors of myeloid lineage Treatment options are rather limited, primarily based on chemotherapy, and often result in disease progression Recently, venetoclax-based therapies have transformed the frontline regimens of elderly patients and patients unfit for intensive chemotherapy. Despite its promising outcomes in clinical studies, multiple resistant subclones evolved during the treatment acting as a barrier in disease regression Understanding the venetoclax-resistance mechanisms and detecting the major determinants could reveal previously unrecognized novel perspectives for therapeutic strategies to improve patients’ outcomes. Moreover, performing high-throughput screenings with clinically approved drugs could reveal novel treatment options for resistant subclones of AML.
Czech name
—
Czech description
—

Project
<a href="/en/project/LX22NPO5102" target="_blank" >LX22NPO5102: National institute for cancer research</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)